Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.40 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TACR2 | P21452 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL944361 | 1.00 | P2RX3 (0.41) | P2RX3HPGDKCNJ5KCNJ3CA2 | |
| SCHEMBL23374815 | 1.00 | P2RX3 (0.41) | P2RX3HPGDKCNJ5KCNJ3CA2 | |
| SCHEMBL15077459 | 0.83 | MAPK14 (0.42) | CA2ALDH1A1MAPK14 | |
| SCHEMBL14804163 | 0.81 | P2RX3 (0.47) | P2RX3KCNJ5KCNJ3CA2 | |
| SCHEMBL13125279 | 0.80 | MRGPRX4 (0.46) | P2RX3HPGDKCNJ5KCNJ3LMNA | |
| SCHEMBL382940 | 0.80 | APP (0.48) | HPGDCA2CYP1A2ALDH1A1MAPT | |
| SCHEMBL3598217 | 0.80 | APP (0.48) | HPGDCA2CYP1A2ALDH1A1MAPT | |
| SCHEMBL251926 | 0.80 | APP (0.48) | HPGDCA2CYP1A2ALDH1A1MAPT | |
| SCHEMBL12673084 | 0.78 | ALDH1A1 (0.46) | CA2ALDH1A1MAPK14 | |
| SCHEMBL12800745 | 0.77 | P2RX3 (0.39) | P2RX3KCNJ5KCNJ3CA2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023152691-A1 | PROCESS FOR THE PREPARATION OF PONESIMOD AND ITS INTERMEDIATES THEREOF | METROCHEM API PVT LTD (IN) | 2023-08-17 | — | — | WO | disclosed |
| US-11014940-B1 | Thiazolidinone and oxazolidinone compounds and formulations | CELGENE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014940-B1 | Thiazolidinone and oxazolidinone compounds and formulations | CELGENE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-9000018-B2 | Thiazolidin-4-one-derivatives | ACTELION PHARMACEUTICALS, LTD (CH) | 2015-04-07 | — | — | US | disclosed |
| US-RE45174-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20130310432-A1 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-21 | — | — | US | disclosed |
| US-8524752-B2 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-03 | — | — | US | disclosed |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2012-11-29 | — | — | US | disclosed |
| US-RE43833-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-RE43728-E1 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-09 | — | — | US | disclosed |
| US-8273779-B2 | 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one; {2-[4-(2-([Z]-isopropylimino)-4-oxo-3-phenyl-thiazolidin-5-[Z]-ylidenemethyl)-phenoxy]-ethoxy}-acetic acid; immunosuppressant agents; multiple sclerosis, psoriasis | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2295418-A1 | 5-(benz-(z)-ylidene)-thiazolidin-4-one derivatives as immunosuppressant agents | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-16 | — | — | EP | disclosed |
| US-7875726-B2 | Thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-25 | — | — | US | disclosed |
| EP-1689726-B1 | 5-(BENZ- (Z) -YLIDENE) -THIAZOLIDIN-4-ONE DERIVATIVES AS IMMUNOSUPPRESSANT AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-06 | — | — | EP | disclosed |
| US-7626037-B2 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-01 | — | — | US | disclosed |
| US-20090275625-A1 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES | VANDA PHARMACEUTICALS INC. | 2009-11-05 | — | — | US | disclosed |
| US-20080280962-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-11-13 | — | — | US | disclosed |
| US-7435828-B2 | immunosuppressive agents; low dosages; 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-o-tolyl-thiazolidin-4-one | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | disclosed |
| US-20080146629-A1 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ACTELION PHARMACEUTICALS, LTD. (CH) | 2008-06-19 | — | — | US | disclosed |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | ACTELION PHARMACEUTICALS, LTD. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310432-A1 | NOVEL THIAZOLIDIN-4-ONE-DERIVATIVES | TLR4, IRF3, IL4 | P2RX3 552/4885HPGD 1302/4885KCNJ5 2820/4885 |
| US-20070082933-A1 | Novel thiazolidin-4-one derivatives | TLR4, IL4, IRF3 | P2RX3 473/4885HPGD 1505/4885KCNJ5 2545/4885 |
| US-20090275625-A1 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES | TLR4, IRF3, TLR1 | P2RX3 480/4885HPGD 1375/4885KCNJ5 2809/4885 |
| US-20080146629-A1 | 5-Benzylidene-2-imino- or hydrazonothiazolidin-4-one derivatives, e.g., 5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-2-([Z]-isopropylimino)-3-phenyl-thiazolidin-4-one and 2-(dimethyl-hydrazono)-5-[4-(2-hydroxy-ethoxy)-benz[Z]ylidene]-3-phenyl-thiazolidin-4-one; immunosuppressant agents | ICOS, IL2, IKZF3 | P2RX3 704/4885HPGD 362/4885KCNJ5 538/4885 |
| US-11014940-B1 | Thiazolidinone and oxazolidinone compounds and formulations | IL17A, OXA1L, ACOX1 | P2RX3 2229/4885HPGD 783/4885KCNJ5 1853/4885 |
| US-20120302612-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | TLR4, IL4, IRF3 | P2RX3 473/4885HPGD 1505/4885KCNJ5 2545/4885 |
| US-20080280962-A1 | NOVEL THIAZOLIDIN-4-ONE DERIVATIVES | TLR4, IL4, IRF3 | P2RX3 473/4885HPGD 1505/4885KCNJ5 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.